Best Growth Stocks to Buy for September 23rd

Zacks highlighted Lifetime Brands, Five Below, and Oscar Health as Zacks Rank #1 (Strong Buy) growth stocks. Current-year consensus EPS estimates increased 6.2% for Lifetime Brands, 15.2% for Five Below, and 210.2% for Oscar Health over the past 60 days. The item is analyst-driven stock-selection commentary rather than new company financial disclosures, implying limited broad market impact.

Analysis

This is a low-information, mechanically positive estimate-revision signal rather than a differentiated fundamental catalyst; no broad rerating should be inferred. The highest-quality read-through is FIVE: upward revisions can become self-reinforcing if comparable-sales recovery and gross-margin delivery force short-covering, but the stock remains highly exposed to lower-income discretionary demand and tariff/freight pressure. The relevant 1-3 month catalyst is the next earnings print and holiday guidance, not the ranking itself.

OSCR has the largest apparent revision momentum but also the greatest model-risk: insurer earnings estimates can move sharply on medical-loss-ratio assumptions, risk-adjustment accruals, and reserve development without changing normalized earnings power. A sustained multiple expansion requires evidence that membership growth is profitable after ACA pricing, not simply that near-term EPS estimates have reset. Watch quarterly MLR, EBITDA guidance, and regulatory developments around enhanced ACA subsidies; adverse subsidy policy would matter more than the current revision trend over 6-18 months.

LCUT is too small and illiquid for a standalone institutional catalyst trade. Its earnings sensitivity is likely driven by retailer replenishment, promotional intensity, and imported-goods costs; improving estimates are vulnerable if consumer demand softens or tariffs/input costs rise. The contrarian view is that consensus screens often attract transient retail flows, while the investable opportunity emerges only where revisions coincide with independently verifiable sales, margin, or cash-flow inflections.

Key Decisions for Investors

• Watch FIVE for a tactical 1-3 month long only if management raises full-year comparable-sales or gross-margin guidance at the next report; target 10-15% upside on a credible recovery versus 7-8% downside using a post-earnings low stop. Avoid chasing a screen-driven pre-earnings move.
• Maintain OSCR as a catalyst watch rather than initiate on estimate revisions alone. Go long only if quarterly MLR and adjusted EBITDA guidance validate profitable growth; use a 5-7% portfolio-risk budget stop on a material MLR miss or evidence of unfavorable ACA-subsidy policy.
• No standalone LCUT position: require confirmation of inventory normalization, positive operating cash flow, and stable gross margin before considering exposure. If liquidity is required, express a consumer-recovery view through FIVE rather than LCUT.
• For sector-neutral exposure, consider long FIVE versus short XRT over the holiday setup only after positive company guidance; the thesis is idiosyncratic execution and margin recovery, with exit if XRT-relative performance fails to improve following results.